- Home
- CNF vs IXHL Comparison
CNF vs IXHL Comparison
Compare CNF & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CNF | IXHL |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 37.0M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CNF | IXHL |
|---|---|---|
| Price | $2.31 | $3.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.9K | ★ 97.0K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.16 |
| 52 Week High | $24.00 | $6.39 |
Technical Indicators
Market Signals| Indicator | CNF | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 48.04 |
| Support Level | $2.12 | $3.07 |
| Resistance Level | $3.39 | $3.68 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 43.59 | 68.75 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.